Recruiting at: Royal Melbourne Hospital
Primary Investigator: Professor Geoff Lindeman
Clinical trial register: ACTRN12614000694617
A pre-operative window study evaluating the biological effects of the RANK-Ligand (RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 or BRCA2 mutation carriers and high-risk non-carriers.
Premenopausal women with a BRCA1 or BRCA2 mutation who are planning to have prophylactic mastectomy OR willing to have two breast biopsies are likely to be eligible for inclusion.